The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine — Worldwide, 2016
Open accessAbstract
Since the 1988 World Health Assembly resolution to eradicate poliomyelitis, transmission of the three types of wild poliovirus (WPV) has been sharply reduced (1). WPV type 2 (WPV2) has not been detected since 1999 and was declared eradicated in September 2015. Because WPV type 3 has not been detected since November 2012, WPV type 1 (WPV1) is likely the only WPV that remains in circulation (1). This marked progress has been achieved through widespread use of oral poliovirus vaccines (OPVs), most commonly trivalent OPV (tOPV), which contains types 1, 2, and 3 live, attenuated polioviruses and has been a mainstay of efforts to prevent polio since the early 1960s. However, attenuated polioviruses in OPV can undergo genetic changes during replication, and in communities with low vaccination coverage, can result in vaccine-derived polioviruses (VDPVs) that can cause paralytic polio indistinguishable from the disease caused by WPVs (2). Among the 721 polio cases caused by circulating VDPVs (cVDPVs*) detected during January 2006-May 2016, type 2 cVDPVs (cVDPV2s) accounted for >94% (2). Eliminating the risk for polio caused by VDPVs will require stopping all OPV use. The first stage of OPV withdrawal involved a global, synchronized replacement of tOPV with bivalent OPV (bOPV) containing only types 1 and 3 attenuated polioviruses, planned for April 18-May 1, 2016, thereby withdrawing OPV type 2 from all immunization activities (3). Complementing the switch from tOPV to bOPV, introduction of at least 1 dose of injectable, trivalent inactivated poliovirus vaccine (IPV) into childhood immunization schedules reduces risks from and facilitates responses to cVDPV2 outbreaks. All 155 countries and territories that were still using OPV in immunization schedules in 2015 have reported that they had ceased use of tOPV by mid-May 2016.(†) As of August 31, 2016, 173 (89%) of 194 World Health Organization (WHO) countries included IPV in their immunization schedules.(§) The cessation of tOPV use is a major milestone toward the global goal of eradicating polio; however, careful surveillance for polioviruses and prompt, aggressive responses to polio outbreaks are still needed to realize a polio-free world.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Complete eradication worldwide will ultimately require the cessation of use of trivalent OPV, a strategy currently being implemented by the WHO through a synchronized switch to a bivalent oral polio vaccine, successfully implemented in 150 countries as of 2016 (Hampton et al., 2016).”
From Vaccine Safety: Myths and Misinformation (2020) · cites this paper as Hampton et al., 2016
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global polio eradication initiative
Koenig‐Archibugi, M. (2011) · London School of Economics and Political Science Research Online (London School of Economics and Political Science) · Cited by 523
Turner, N., & Strategic Advisory Group of Experts (2018) · American Academy of Pediatrics eBooks · doi:10.1542/9781610021494-part06-meeting_of_the_strate · Cited by 348
Update on Vaccine-Derived Polioviruses-Worldwide, January 2017–June 2018
Jorba, J., Diop, O. M., Iber, J., Henderson, E., Zhao, K., Sutter, R. W., Wassilak, S. G. F., & Burns, C. C. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6742a5 · Cited by 197
Self-citationProgress Toward Polio Eradication — Worldwide, 2015–2016
Morales, M., Tangermann, R. H., & Wassilak, S. G. F. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6518a4 · Cited by 182
Self-citationUpdate on Vaccine-Derived Polioviruses — Worldwide, January 2015–May 2016
Jorba, J. C., Diop, O. M., Iber, J. C., Sutter, R. W., Wassilak, S. G. F., & Burns, C. C. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6530a3 · Cited by 60
Self-citationTebbens, R. J. D., Hampton, L. M., & Thompson, K. M. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1537-8 · Cited by 49
Self-citationTebbens, R. J. D., Hampton, L. M., & Thompson, K. M. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1536-9 · Cited by 46
Self-citationSurveillance Systems to Track Progress Toward Polio Eradication — Worldwide, 2014–2015
Snider, C. J., Diop, O. M., Burns, C. C., Tangermann, R. H., & Wassilak, S. G. F. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6513a3 · Cited by 39
Self-citationEtsano, A., Damisa, E., Shuaib, F. M. B., Nganda, G. W., Enemaku, O., Usman, S., Adeniji, A., Jorba, J. C., Iber, J. C., Ohuabunwo, C. J., et al. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6530a4 · Cited by 39
Previsani, N., Tangermann, R. H., Tallis, G. F., & Jafari, H. S. (2015) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6433a5 · Cited by 35
Cited by
Sorted by citations
Vaccine Safety: Myths and Misinformation
Geoghegan, S., O’Callaghan, K. P., & Offit, P. A. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00372 · Cited by 275
“Given this landscape it is crucial that there is a focused effort to improve confidence in vaccine safety during pregnancy among both pregnant women and providers (Heath et al., 2017).”
BackgroundUpdate on Vaccine-Derived Polioviruses-Worldwide, January 2017–June 2018
Jorba, J., Diop, O. M., Iber, J., Henderson, E., Zhao, K., Sutter, R. W., Wassilak, S. G. F., & Burns, C. C. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6742a5 · Cited by 197
Self-citationWastewater-based surveillance as a tool for public health action: SARS-CoV-2 and beyond
Parkins, M. D., Lee, B. E., Acosta, N., Bautista, M. A., Hubert, C. R. J., Hrudey, S. E., Frankowski, K., & Pang, X. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00103-22 · Cited by 189
Perspective on Global Measles Epidemiology and Control and the Role of Novel Vaccination Strategies
Coughlin, M. M., Beck, A. S., Bankamp, B., & Rota, P. A. (2017) · Viruses · doi:10.3390/v9010011 · Cited by 154
Macklin, G., O’Reilly, K. M., Grassly, N. C., Edmunds, W. J., Mach, O., Krishnan, R. S. G., Voorman, A., Vertefeuille, J. F., Abdelwahab, J., Gumede, N., et al. (2020) · Science · doi:10.1126/science.aba1238 · Cited by 146
Self-citation
Metadata
- Authors
- Hampton, L. M., Farrell, M., Ramirez-Gonzalez, A., Menning, L., Shendale, S., Lewis, I., Rubin, J., Garon, J., Harris, J., Hyde, T., Wassilak, S., Patel, M., Nandy, R., Chang-Blanc, D., & Immunization Systems Management Group of the Global Polio Eradication Initiative
- Affiliations
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Hampton, Lee M.
- ORCID
- Venue
- MMWR Morbidity and Mortality Weekly Report
- Published
- 2016-09-09
- Volume
- 65
- Issue
- 35
- Pages
- 934-938
- ISSN
- 0149-2195 (ISSN-L)
- 1545-861X
- OpenAlex
- W2510158554
- Cited by
- 193
- References
- 11
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 13 · 2023: 24 · 2022: 17 · 2021: 19 · 2020: 25 · 2019: 16 · 2018: 29 · 2017: 27 · 2016: 6
- FWCI
- 21.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- MMWR Morbidity and Mortality Weekly Report (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health and Human Services
- Centers for Disease Control and Prevention
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- trivalent oral polio vaccine, inactivated poliovirus vaccine, vaccine-derived poliovirus, poliovirus type 2, bivalent oral poliovirus vaccine, polio eradication, wild poliovirus, polio vaccination coverage, childhood immunization schedule, polio surveillance
- MeSH terms
- Disease Outbreaks, Humans, Poliomyelitis, Poliovirus Vaccine, Inactivated, Poliovirus Vaccine, Oral, Global Health, Drug Substitution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
